The implications for the community and the National Health Service of treating mild as well as severe hypertension are alarming. In the Whitehall screening study of some 20 000 middleaged male civil servants, about 20 % were found to have diastolic pressures greater than 95 mmHg. It is important that the indications for starting treatment of mild hypertension are clearly defined and, as there is a bewilderingly large choice of treatments, that objective evidence should be available to ensure proper assessment of their effects.
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When hypotensive drugs were first introduced and used in the treatment of malignant hypertension, clinical impression was an adequate guide to benefits. However, follow up among the civil servants with diastolic pressures above 95 mmHg has shown that only 4% of that group had died of cardiovascular disease after five years. Although that is a four-fold increase above the mortality for the normotensive group, it still means that after five years, in a group with mild/ moderate hypertension, 96 % are alive and probably something like 92 % have had no major complication. In that situation even a moderately large reduction in the complication rate is not going to be self-evident and the complications of treatment may also not be revealed. The practololinduced skin and eye changes were most unusual and rather specific complications which were therefore relatively obvious, but the possibility must also be considered that long-term use of hypotensive drugs may increase the incidence of common and familiar conditions whose detection would be that much harder. An example from another field is clofibrate, which for many years was thought to be a very safe drug. It was not until the results of the randomized controlled trial of clofibrate in the secondary prevention of myocardial infarction in the Coronary Drug Project that it was learnt that, compared with a placebo group, there was a significant increase in deep venous thrombosis and pulmonary embolism, gallstones, and three or four other rather unpleasant conditions. The possibility that the benefits which are received by a minority of those treated in drug trials may be outweighed by a low complication rate applied to a large number of people must always be borne in mind. Since the balance of effects may prove to be adverse, the design must always be based on two-tailed significance testing. It is only by the use of control groups that such questions can adequately be answered, and in a controlled trial the hallmark of honesty is randomization.
Problems in Assessing Hypotensive Therapy
Regressioni to the mean: When candidates for hypotensive therapy are initially examined, a certain number will be found to have blood pressures above a certain cut-off point, and these subjects include not only those whose mean blood pressure is truly elevated but others in whom that single measurement just happened to coincide with an exceptionally high moment in their pressure curve. Therefore, when these 'hypertensive' subjects are reexamined later, there will inevitably be a fall in the mean pressure because those who happened to be high on the first occasion will not generally happen to be high on the second. To start treatment after one examination would thus be predictably successful. At least two or three baseline measurements, taken on separate days, are essential. Effect of circumstances: Trials are frequently published which define, with apparently great precision, the criteria for treatment, such as 'a diastolic blood pressure of 95 to 104 mmHg'. This precision is illusory because if the same group of patients had had their blood pressures measured not in a hospital clinic by doctors, but by reassuring nurses, or by GPs in the surgery, or at home, the whole distribution of pressures might have been shifted considerably. Blood pressure is a measurement which cannot be standardized and for which there is no proper calibrating mechanism, but bias can be reduced by standardizing the conditions for measurement as far as possible. Systems are available for training observers and for quality control, but in the final analysis, great caution has to be exercised in comparing the results of any trial to blood pressures measured in other circumstances. Observer bias: Everyone believes himself to be free of bias, but when trials are reported, justice must not only have been done, it must also be seenby highly sceptical readersto have been done. Blood pressure is easily biased by the observer's expectations and the ideal solution in any trial design is to have a double-blind system. This may be impracticable when dealing with variable dose regimes and, moreover, doubleblindness can easily be lost if the side effects of drugs make them identifiable to patients or doctors, which is all too commonly the case. Where a double-blind system cannot be built into the design or cannot successfully be maintained, the pressures should be measured by one or other of the special instruments which ensure freedom from observer bias. Patient habituation: In the MRC trial of treatment for mild/moderate hypertension, we have observed gratifying falls in blood pressure in each of the active treatment groups. Unfortunately for the trial, about half of the fall seen in the active drug group also occurs in the placebotreated patients, so that the specific effect of the drugs is only about half what might have been supposed. The patients over a period of two or three months seemingly get used to having their blood pressure taken; as a consequence they are more relaxed and their pressures fall. Because of this it is impossible to measure reliably the hypotensive effect of a particular drug unless there is an untreated control group. It also means that in any trial the frequency of follow-up visits should be the same in all groups, as patients who are seen at weekly intervals will tend to have a greater fall in BP because of greater habituation than others who are seen less frequently.
Assessment ofSide Effects
The assessment of side effects will obviously be influenced by the patient's and the observer's expectations. If the design cannot be double-blind then it should at least be single-blind as far as the patient is concerned, and the assessment of side effects can be made by a standard questionnaire, preferably self-administered, so that observer bias is removed. In the MRC trial a self-administered psychiatric questionnaire on mental wellbeing is being given to sub-samples of the main trial to try and assess the frequency of the minor psychological disturbances that may accompany hypotensive drug therapy. Assessment of the clinical endpoints of the trial is also subject to observer bias. It is widely understood that the criteria for endpoints must be strictly defined, but it is not widely understood that strict definition is not sufficient. If the information by which the critical events is to be assessed is collected differently in different groups of patients there may well be bias in the overall assessment of the incidence of events. For example, a patient known to be having the active drug may attend more frequently and hence be more likely to have an ECG taken in the event of chest pain. If the ECG is then sent to an external referee this cannot remove the bias that was built into the collection of the information. If the trial is not double-blind the information by which endpoints are assessed must be collected with equal thoroughness and frequency in the groups to be compared.
Duration ofTrials
The duration of these trials raises severe problems. In the first Veterans Administration trial in moderately severe hypertension there was no such problem because, within an average follow up of three years, there was a large and significant benefit of treatment. But to assess the effects of treating milder hypertension we envisage much longer periods of time. The first problem this can raise is what might be called the 'stroke barrier' which brought the second Veterans Administration trial to a halt. The main hazard of mild to moderate hypertension is the long-term excess of coronary disease, and if a trial is brought to a halt because it quickly shows a beneficial effect on the occurrence of stroke, the crucial question -'what effect would longer treatment have had on the coronary risk ?' -remains unanswered. Fortunately, as the severity of hypertension is reduced, the ratio of myocardial infarction to stroke increases. In the middle-aged male civil servants with diastolic pressures at screening of 100 mmHg, the five-year ratio of fatal myocardial infarction to fatal stroke was 7 to 1; in the MRC tiial it is hoped that again a relative excess of coronary events will permit the trial to continue long enough to answer the question of the effect on coronary heart disease.
It may be difficult to keep a trial alive for a long time as patients are inevitably transferred from the group of treatment to which they were initially allocated and there are losses to follow up. Fortunately there are back-up systems, such as the Central Registry of the National Health Service at Southport, which permit virtually complete follow up at least for mortality. In long-term trials the investigator as well as the patients may drop out. If a trial is to continue for a long time, no one person should be essential to its continuation; there must be understudies. Furthermore, the investigator must consider whether, at the end of five years, the drug with which the trial started will still be of interest, or whether it will have been overtaken by new products. Most fundamentally of all, how would the profit and loss accounts for treatment stand after many years? The decision we have to make is whether or not to embark on a lifetime of treatment for mild to moderate hypertension; but the balance of the profits and losses after three, four or five years of a trial may not be the same as the balance after 10, 20, or 30 years. There is no hope that trials will continue for the length of time required to answer that vital question adequately. After five years in a trial of mild to moderate hypertension no more than perhaps 10% of middle-aged people will have benefited from the treatment and 90 % would have been all right anyway; but 100% are committed to a lifetime of treatment and long-term exposure to the unknown effects of treatment. This, which is the most important question of all, cannot be answered by controlled trials.
Trial Numbers
The MRC trial was planned to include sufficient subjects to detect a 40 % reduction in fatal stroke and hypertension. Ideally the power to detect a much smaller benefit would have been preferable but even that relatively large effect requires approximately 90 000 patient/years of observation, and to identify a sufficient number of suitable subjects (diastolic range 90 to 109 mmHg) may require screening half a million of the population. That is the scale of trial needed to measure the medium-term benefits and costs of treating mild to moderate hypertension. There are obviously other objectives of trials which do not require such large numbers, as in trials that compare the effects on blood pressure and sideeffects in the short-term of one drug against another. Before any trial is started the investigator should, with the help of a statistician if he is not one himself, first ask himself the question, 'How much have I got to spend?' Then, 'How many subjects for how long will these resources purchase?' and 'Will that amount of observation answer the questions posed?'
Conclusion
Randomized controlled trials of hypotensive drugs are difficult and costly, and therefore they should be started selectively. To avoid duplication there should perhaps be fewer but better trials. Randomized controlled trials are crude and relatively insensitive instruments: they may not detect effects which clinically would be interesting, and they leave some of the major questions unanswered. But for all their drawbacks they are objective, honest and quantitative, and they offer the best available guide to therapy.
